medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2015, Number 3

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2015; 31 (3)

Anti-C1q antibodies in hepatitis C virus infection

Merlín LJC, Villaescusa BR, Guerreiro HAM, Leyva RA, Arce HAA

Language: Spanish
References: 26
Page: 324-330
PDF size: 92.38 Kb.


ABSTRACT

Hepatitis C often develops into a chronic disease with several extrahepatic manifestations, autoimmunity, and the possible formation of autoantibodies with different specificities. C1q deficiency affects the elimination of infected cells by apoptosis, the maintenance of immunological tolerance and it also favors the development of systemic lupus erythematosus in particular and of autoimmune phenomena in general, all of which could be exacerbated by the presence of anti- C1q. In this study, the prevalence of anti-C1q antibodies in 39 patients (23 females and 16 males) and 109 controls was determined by an ELISA type immunoassay (Anti-C1q ORGENTEC Diagnostika GmbH). A significantly higher frequency (p ‹ 0.05) of these autoantibodies was observed in the patients group than in the control group. When separating the patients according to sex, the proportion of positive cases were significantly higher (p ‹ 0.05) in females; and when the patients were divided into a group of 14 hematological and 25 nonhematological the proportion of cases with anti -C1q in the hematological group was lower. We concluded that it would be important to perform a longitudinal evaluation of our patients that will allow us to detect the early appearance of autoantibodies, to deepen our knowledge of their possible connection to autoimmune conditions, to the appearance of other autoantibodies, as well the possible influence of treatment.


REFERENCES

  1. Selvarajah S, Keating S, Heitman J, Lu K, Simmons G, Norris PJ, et al. Detection of host immune responses in acute phase sera of spontaneous resolution versus persistent hepatitis C virus infection. J Gen Virol. 2012 Ago;93(Pt 8):1673-9.

  2. Grebely J, Prins M, Hellard M, Cox AL, Osburn WO, Lauer G, et al. Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis. 2012 May;12(5):408-14.

  3. Irshad M, Mankotia DS, Irshad K. An insight into the diagnosis and pathogenesis of hepatitis C virus infection. World J Gastroenterol. 2013 Nov;19(44):7896-909.

  4. Schamberg NJ, Lake-Bakaar GV. Hepatitis C Virus-related Mixed Cryoglobulinemia. Gastroenterol Hepatol. 2007 Sept;3(9):695-703.

  5. Himoto T, Masaki T. Extrahepatic Manifestations and Autoantibodies in Patients with Hepatitis C Virus Infection. Clin Dev Immunol. 2012;2012:87140-1. doi: 10.1155/2012/871401.

  6. Minopetrou M, Hadziyannis E, Deutsch M, Tampaki M, Georgiadou A, Dimopoulou E, et al. Hepatitis C Virus (HCV)-Related Cryoglobulinemia: Cryoglobulin Type and Anti -HCV Profile. Clin Vaccine Immunol. 2013 May;20(5):698-703.

  7. Tampaki M, Koskinas J. Extrahepatic immune related manifestations in chronic hepatitis C virus infection. World J Gastroenterol. 2014 Sep;20(35):12372-80.

  8. Fabris P, Floreani A, Tositti G, Vergani D, De Lalla F, Betterle C. Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy. Aliment Pharmacol Ther. 2003 Sept;18(6):549-58.

  9. Naing C, Mak JW, Ahmed SI, Maung M. Relationship between hepatitis C virus infection and type 2 diabetes mellitus: Meta-analysis. World J Gastroenterol. 2012 Abr;18(14):1642-51.

  10. Williams MJ, Lawson A, Neal KR, Ryder SD, Irving WL, on behalf of the Trent HCV Group. Autoantibodies in chronic hepatitis C virus infection and their association with disease profile. J Viral Hepat. 2009 May;16(5):325-31.

  11. Mollejo M, Menárguez J, Guisado-Vasco P, Bento L, Algara P, Montes-Moreno S, et al. Hepatitis C virus-related lymphoproliferative disorders encompass a broader clinical and morphological spectrum than previously recognized: a clinic pathological study. Mod Pathol. 2014 Feb;27(2):281-93.

  12. Guerreiro AM, Villaescusa R, Morera LM, González Y, Arce AA, Merlín JC, et al. Determinación de autoanticuerpos en pacientes con hemopatías malignas y hepatitis C. Rev Cubana Hematol Inmunol Hemoter. 2001 Ago;17(2):142-3.

  13. Bantel H, Schulze-Osthoff K. Apoptosis in hepatitis C virus infection. Cell Death Differ. 2003 Ene;10(S1):S48-58.

  14. Antonelli A, Ferri C, Galeazzi M, Giannitti C, Manno D, Mieli-Vergani G, et al. HCV infection: pathogenesis, clinical manifestations and therapy. Clin Exp Rheumatol. 2008 Feb;26(1 Suppl 48):S39-47.

  15. Roughan JE, Reardon KM, Cogburn KE, Quendler H, Pockros PJ, Law M. Chronic Hepatitis C Virus Infection Breaks Tolerance and Drives Polyclonal Expansion of Autoreactive B Cells. Clin Vaccine Immunol. 2012 Jul;19(7):1027-37.

  16. Boţianu A-M, Demian S, Macarie I, Georgescu D, Oltean G, Băţagă S. Acquired haemophilia complicated with gastrointestinal bleeding and spontaneous iliopsoas muscle haematoma in a woman with chronic C hepatitis under treatment with pegylated IFN alpha 2a and ribavirin. J Gastrointest Liver Dis. 2012 Mar;21(1):93-5.

  17. Berg CP, Schlosser SF, Neukirchen DK, Papadakis C, Gregor M, Wesselborg S, et al. Hepatitis C virus core protein induces apoptosis-like caspase independent cell death. Virol J. 2009;6(1):213.

  18. Di Lorenzo C, Angus AGN, Patel AH. Hepatitis C Virus Evasion Mechanisms from Neutralizing Antibodies. Viruses. 2011 Nov;3(11):2280-300.

  19. Kim S-J, Syed GH, Khan M, Chiu W-W, Sohail MA, Gish RG, et al. Hepatitis C virus triggers mitochondrial fission and attenuates apoptosis to promote viral persistence. Proc Natl Acad Sci. 2014 Abr;111(17):6413-8.

  20. Campos-de-Magalhães M, Eduardo Brandão-Mello C, Lúcia Elias Pires M, Cecília da Fonseca Salgado M, Barcelo de Brito S, José de Almeida A. Factor VIII and IX deficiencies related to acquired inhibitors in a patient with chronic hepatitis C virus infection receiving treatment with pegylated interferon plus ribavirin. Hematol Amst Neth. 2011 Mar;16(2):80-5.

  21. Bencomo A, Gutiérrez A, Ávila O, Ramón L. Caracterización de los autoanticuerpos en la anemia hemolítica autoinmune secundaria al tratamiento con interferón alfa. Rev Cubana Hematol Inmunol Hemoter. 2012 Mar;28(1):41-52.

  22. Ustariz C, García CU. Diabetes mellitus tipo 1 en paciente con hepatitis C tratada con interferón α. Primer caso en Cuba. Rev Cubana Hematol Inmunol Hemoter. 2013;29(3):284-8.

  23. Arocas V, Fernández de Palencia MÁ, Garrido B, de la Rubia A. Acquired haemophilia A in a patient with chronic hepatitis C virus infection receiving treatment with pegylated interferon plus ribarivin: role of rituximab. Farm Hosp Órgano Of Expr Científica Soc Esp Farm Hosp. 2013 Dic;37(6):494-8.

  24. Saadoun D, Sadallah S, Trendelenburg M, Limal N, Sene D, Piette JC, et al. Anti-C1q antibodies in hepatitis C virus infection. Clin Exp Immunol. 2006 Ago;145(2):308-12.

  25. Pickering MC, Botto M. Are anti-C1q antibodies different from other SLE autoantibodies? Nat Rev Rheumatol. 2010 Ago;6(8):490-3.

  26. Mahler M, van Schaarenburg RA, Trouw LA. Anti-C1q Autoantibodies, Novel Tests, and Clinical Consequences. Front Immunol. 2013: May;4:117. doi:10.3389/fimmu.2013.00117.




2020     |     www.medigraphic.com